PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH COVETRUS NORTH AMERICA, LLC
2023年12月22日 - 10:00PM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an
emerging biomedical device company focused on the commercialization
of innovative medical devices and other therapeutics for equine and
companion animals, announced today it has entered into a definitive
distribution agreement with Covetrus North America, LLC
(“Covetrus”). Covetrus will inventory, market and promote PetVivo’s
veterinary medical device, Spryng™ with OsteoCushion™ technology,
throughout the United States. Covetrus sales and marketing
activities will commence on January 1, 2024.
"We are incredibly pleased to add Covetrus to
our current distribution network to distribute our signature
product, Spryng with OsteoCushion technology. By adding Covetrus to
our current distribution network, they will assist PetVivo as
another strategic partner that will allow our Company significant
exposure to and penetration in the US animal health market. We
believe this new relationship will benefit the veterinary industry,
the veterinarians who provide the medical care to their patients,
the animals receiving Spryng as well as the owners benefiting from
the enhanced medical outcomes of their animals," stated John Lai,
Chief Executive Officer for PetVivo Holdings, Inc.
SPRYNG™ with OsteoCushion™ Technology, is an
intra-articular injectable veterinary medical device consisting of
sterilized, extra-cellular matrix microparticles. The
microparticles of Spryng have been found to adsorb onto the joint
synovial lining of animals and subsequently integrate with the
animal’s subsynovial tissue. Such action promotes the restoration
of proper joint mechanics, thereby aiding in the management of
noninfectious sources of joint pain such as joint instability,
degenerative joint disease and osteoarthritis.
For more information about PetVivo Holdings,
Inc. and its innovative product, Spryng, please contact
info1@petvivo.com or visit https://petvivo.com/ and
https://sprynghealth.com/.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of twenty patents
protects the Company's biomaterials, products, production processes
and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint-related afflictions,
including osteoarthritis, in dogs and horses, is currently
available for commercial sale to veterinarians.
CONTACT:
John Lai, CEO PetVivo Holdings, Inc. Email:
info1@petvivo.com (952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2023 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETVW)
過去 株価チャート
から 8 2024 まで 9 2024
PetVivo (NASDAQ:PETVW)
過去 株価チャート
から 9 2023 まで 9 2024